Clinical Trial Update: A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 trial to evaluate subcutaneous anifrolumab for systemic lupus erythematosus in immunosuppressant-naïve and biologic-naïve patients; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: NOT_YET_RECRUITING